AOD-9604
Advanced Obesity Drug 9604
Potential Benefits
- Preclinical studies suggest stimulation of lipolysis (fat breakdown)
- May inhibit lipogenesis (new fat formation) based on animal models
- Does not appear to affect blood sugar or promote growth, unlike full GH
- Research suggests potential benefits for cartilage repair (studied by a separate group)
- GRAS (Generally Recognized as Safe) status granted by FDA for food use
Recommended Starting Dose
250-300 mcg subcutaneously per day
Based on published research protocols. Not a prescription.
Dosing Protocol
Typically injected subcutaneously once daily in the morning on an empty stomach at 250-500 mcg. Some protocols use divided doses. Cycles of 12 weeks are common, followed by a break. Fasting for 30 minutes after injection is often recommended.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Anecdotal reports suggest initial changes in body composition may appear at 4-8 weeks. Clinical trial data did not demonstrate strong efficacy for weight loss as a monotherapy.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Limited published human safety data from clinical trials
- Injection site reactions
- Headache reported in some trial participants
- Clinical trials for obesity did not meet primary efficacy endpoints
- Long-term effects are not well-characterized
More in Weight Loss
Retatrutide
Retatrutide (Triple G Receptor Agonist)
Retatrutide is an investigational triple hormone receptor agonist (GLP-1, GIP, and glucagon receptors) developed by Eli Lilly. By targeting all three incretin and metabolic pathways simultaneously, it has demonstrated unprecedented efficacy in early clinical trials for obesity, resulting in up to 24.2% body weight reduction over 48 weeks—currently surpassing single and dual-agonists in trial comparisons.
Tirzepatide
Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist developed by Eli Lilly. It activates both incretin pathways, producing effects on insulin secretion, glucagon suppression, appetite, and body weight. It is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.